[Product Monograph Template - Standard]
Avant l'administration du traitement par COTELLIC en association avec le vémurafénib la présence d'un mélanome à mutation BRAF V600 doit être confirmée par un
Cotellic PM F
PrCOTELLIC
5 jan. 2018 As COTELLIC is used in combination with vemurafenib refer also to the ZELBORAF® (vemurafenib). Product Monograph.
Cotellic PM E
Cotellic INN-cobimetinib
28 août 2015 Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma ...
cotellic epar product information en
Reference ID: 3938960 1
COTELLIC® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K.
s lbl
DRUG NAME: Cobimetinib
1 sept. 2017 COTELLIC® product monograph. Mississauga Ontario; 3 February 2017. BC Cancer Agency Cancer Drug Manual©. Page 6 of 6. Cobimetinib.
Cobimetinib monograph Sep
cobimetinib (Cotellic®) vemurafenib (Zelboraf®)
25 nov. 2020 (Cotellic). Unresectable or metastatic melanoma with a BRAF V600E or. V600K mutation. 20 mg tablets. 63 tablets/28 days vemurafenib.
zanubrutinib Brukinsa
cobimetinib
Drug Monograph. Drug Name Mechanism of Action and Pharmacokinetics
cobimetinib ?download=
How does COTELLIC work?
5 jan. 2018 COTELLIC is used to treat adult patients with a type of skin cancer ... Find the full product monograph that is prepared for healthcare ...
Cotellic PM CIE
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION
21 juil. 2022 TECENTRIQ® indicated for: • in combination with carboplatin and etoposide for the first-line treatment of adult patients.
Tecentriq PM CIE
pan-Canadian Oncology Drug Review Final Clinical Guidance
30 jui. 2016 pCODR Final Clinical Guidance Report – Cobimetinib (Cotellic) for Metastatic Melanoma. pERC Meeting: April 21 2016; pERC Reconsideration ...
pcodr cobimetinib cotellic metmela fn cgr